Here's a list of key deals reported across sectors this week: ...

Amazon (AMZN) looks like a GARP buy with PEG under 1x and double-digit return potential—driven by AWS, AI, and retail ...

Innovative Industrial Properties (IIPR) analysis: 13.4% dividend yield, low leverage & cannabis tailwinds—plus key risks. See ...

Hershey delivered a Q2 double beat, raised full-year guidance, and now trades at 17.7x 2027 EPS with a 3.32% yield. Read why ...

NVDX achieves 2x daily exposure to NVDA via swap agreements, not by holding the underlying stock. Find out why NVDX ETF is a ...

Everspin is the leading standalone magnetoresistive memory supplier and product demand is accelerating. Find out why MRAM ...

CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP ...

TYG offers a 13.27% yield but has significantly underperformed both the energy sector and peer funds year-to-date. Learn why ...

Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.

VYM's composition seems to adapt well to the economic context on which the US economy continues to insist. Click for more on ...

Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing ...

Dry bulk fundamentals improve beyond headlines, supporting a strong buy on Seanergy and a buy on Star Bulk. Read why segment ...